FOLD vs. ALKS, MDGL, GERN, BBIO, DVAX, IRWD, LGND, MNKD, INVA, and OPK
Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Alkermes (ALKS), Madrigal Pharmaceuticals (MDGL), Geron (GERN), BridgeBio Pharma (BBIO), Dynavax Technologies (DVAX), Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), MannKind (MNKD), Innoviva (INVA), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
Amicus Therapeutics (NASDAQ:FOLD) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.
In the previous week, Alkermes had 5 more articles in the media than Amicus Therapeutics. MarketBeat recorded 5 mentions for Alkermes and 0 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.26 beat Alkermes' score of 0.78 indicating that Amicus Therapeutics is being referred to more favorably in the media.
Amicus Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
Alkermes has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
95.2% of Alkermes shares are held by institutional investors. 2.1% of Amicus Therapeutics shares are held by company insiders. Comparatively, 4.8% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Alkermes has a net margin of 21.39% compared to Amicus Therapeutics' net margin of -37.96%. Alkermes' return on equity of 16.10% beat Amicus Therapeutics' return on equity.
Amicus Therapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 94.55%. Alkermes has a consensus target price of $35.38, suggesting a potential upside of 43.33%. Given Amicus Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Amicus Therapeutics is more favorable than Alkermes.
Alkermes received 173 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. However, 73.46% of users gave Amicus Therapeutics an outperform vote while only 70.84% of users gave Alkermes an outperform vote.
Summary
Alkermes beats Amicus Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Amicus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amicus Therapeutics Competitors List
Related Companies and Tools
